Lupin Launches Generic Oxcarbazepine ER Tablets in the U.S.

  Published 1 year ago

Lupin's Oxcarbazepine ER tablets are bioequivalent to Oxtellar XR, and treat partial-onset seizures in patients 6+. Manufactured in India. They match the $206 million annual U.S. sales of the reference drug.

  • Available in 150 mg, 300 mg, and 600 mg as a generic alternative to Oxtellar XR.
  • Produced at Lupin's Nagpur facility, ensuring quality and regulatory compliance.
  • Lupin, a global pharmaceutical leader, offers products in over 100 markets with diverse therapeutic options.

You might like these

Apple's Walled Garden Cracks: New Payment Options

Reckitt Beats Q2 Sales Estimates

RBI Rate Cut Weakens Rupee Amid FX Pressures

Reliance Flags Risk from Global Oil Unrest

India's Sugar Stock: Stable Supply & Prices

Oracle Cloud Revenue Surges

Sapphire Foods Q2 FY26 Results Snapshot

News that matters the most ⚡